Tonix Pharmaceuticals Holding Corp.
- Market Cap (Float-Adj) (Float-adjusted market cap computed by the low-float screener — matches the screener row. May differ from the standard cap (price × all shares outstanding) reported elsewhere.)
- $129.5M
- Price
- $7.55
- % Change (Daily % change from the live per-ticker quote feed.)
- -1.88%
- Volume
- 709.4K
About
Tonix Pharmaceuticals Holding Corp. is a biopharmaceutical firm primarily operating in the clinical development stage. Its overarching mission involves the discovery, acquisition, advancement, and commercialization of novel therapeutic agents and diagnostic tools, all aimed at combating human illnesses and easing patient discomfort. The company boasts a comprehensive pipeline of potential treatments spanning several key medical fields: immunology, rare conditions, infectious diseases, and central nervous system (CNS) disorders. In the realm of immunology, Tonix is progressing with biologics designed to address organ transplant rejection, various autoimmune diseases, and certain forms of cancer. A prominent candidate here is TNX-1500, a humanized monoclonal antibody targeting CD40-ligand, which is being investigated for its utility in preventing both allograft and xenograft rejection, as well as in treating autoimmune disorders. Its rare disease initiatives include TNX-2900, a specific treatment candidate for Prader-Willi syndrome. The infectious disease segment features a diverse array of programs: TNX-801, a vaccine designed to offer protection against smallpox and monkeypox. TNX-1840 and TNX-1850, which are live virus vaccines based on the company's recombinant pox vaccine (RPV) platform, targeting COVID-19. TNX-3500, a small molecule antiviral drug for the treatment of acute COVID-19. TNX-102 SL, a small molecule medication under investigation for Long COVID, a persistent post-acute COVID-19 condition. Finally, the CNS portfolio encompasses both small molecules and biologics intended to manage pain, neurological conditions, psychiatric ailments, and addiction. Notably, TNX-102 SL is also in mid-Phase 3 development for alleviating fibromyalgia symptoms. Other CNS candidates include TNX-1900, which is being developed to prevent migraine headaches, and TNX-1300, a biologic aimed at treating cocaine intoxication. The company was established in 2007 and maintains its headquarters in Chatham, New Jersey.
Quick stats
Shares outstanding17.2M
Computed float17.1M
Float / shares99.7%
Cash runway (months)9.5
Key info
SectorHealthcare
IndustryBiotechnology
CIK (Central Index Key — the unique ID the SEC assigns to every filer. Use it to look up the company's filings on EDGAR.)0001430306
Websitehttps://www.tonixpharma.com
AI Summary
AI-generated1/43
standardbullishoperations update
Tonix Pharmaceuticals Announces Second Major Managed Medicare Payer Agreement for TONMYA®
Tonix Pharmaceuticals signed a second major managed Medicare agreement for TONMYA, its newly approved fibromyalgia treatment, effective immediately and adding approximately 21 million Medicare lives.
With the new deal, Medicare coverage totals 32 million lives, and combined commercial and government payer coverage reaches approximately 166 million covered lives, about 53% of the roughly 314 million total U.S. population.
Chief Commercial Officer Thomas Englese said approximately 50 new sales representatives have been fully activated, bringing the total sales force to 150, as the company works to convert expanded coverage into patient access for the drug the FDA approved on August 15, 2025.
Red flags
- No financial terms, pricing, or revenue contribution disclosed for the payer agreements
- TONMYA was only approved August 15, 2025; payer coverage does not guarantee prescription uptake or revenue